安根的新肥胖药《MariTide》显示, 体重下降效果大有希望, 但未能达到市场预期。 Amgen's new obesity drug, MariTide, shows promising weight loss results but fails to meet market expectations.
安根的实验性肥胖药物《MariTide》在第二阶段试验中显示出有希望的结果,病人一年后体重减20%。 Amgen's experimental obesity drug, MariTide, showed promising results in a Phase 2 trial, with patients losing up to 20% of their weight after a year. 该药物每月注射一次,也没有显示体重减退高原和心血管健康状况的改善。 The drug, given monthly by injection, also showed no weight loss plateau and improvements in cardiometabolic health. 尽管取得了这些积极成果,但安根的股票却由于结果没有达到华尔街的高期望而下降。 Despite these positive outcomes, Amgen's stock fell as the results did not meet Wall Street's high expectations. MariTide预计将与其他公司的每周注射相竞争,并可能成为1 500亿美元的肥胖症治疗市场的一个重要参与者。 MariTide is expected to compete with weekly injections from other companies and could be a significant player in the $150 billion obesity treatment market. 常见的副作用包括胃肠问题,如呕吐和恶心。 Common side effects included gastrointestinal issues like vomiting and nausea.